EP2716304A1 - LIPOSOME CONTAINING shRNA MOLECULE FOR THYMIDYLATE SYNTHASE, AND USE FOR SAME - Google Patents
LIPOSOME CONTAINING shRNA MOLECULE FOR THYMIDYLATE SYNTHASE, AND USE FOR SAME Download PDFInfo
- Publication number
- EP2716304A1 EP2716304A1 EP12790050.4A EP12790050A EP2716304A1 EP 2716304 A1 EP2716304 A1 EP 2716304A1 EP 12790050 A EP12790050 A EP 12790050A EP 2716304 A1 EP2716304 A1 EP 2716304A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- antitumor agent
- shrna
- peg
- cationic liposome
- antitumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000004055 small Interfering RNA Substances 0.000 title claims abstract description 112
- 108091027967 Small hairpin RNA Proteins 0.000 title claims abstract description 108
- 239000002502 liposome Substances 0.000 title claims abstract description 81
- 108010022394 Threonine synthase Proteins 0.000 title claims abstract description 10
- 102000005497 Thymidylate Synthase Human genes 0.000 title claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 137
- 125000002091 cationic group Chemical group 0.000 claims abstract description 62
- 239000002773 nucleotide Substances 0.000 claims abstract description 45
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 45
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 33
- 230000009368 gene silencing by RNA Effects 0.000 claims abstract description 31
- 108091030071 RNAI Proteins 0.000 claims abstract description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 65
- 229940127089 cytotoxic agent Drugs 0.000 claims description 35
- 108091081021 Sense strand Proteins 0.000 claims description 32
- 108020004459 Small interfering RNA Proteins 0.000 claims description 31
- 230000000692 anti-sense effect Effects 0.000 claims description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 28
- 229960005079 pemetrexed Drugs 0.000 claims description 20
- ZCTCZKWJFTYNMZ-WKUCUCPSSA-J tetrasodium;(2s)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1.C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 ZCTCZKWJFTYNMZ-WKUCUCPSSA-J 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- -1 POPC Chemical compound 0.000 claims description 15
- 235000012000 cholesterol Nutrition 0.000 claims description 14
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims description 14
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 230000004663 cell proliferation Effects 0.000 claims description 9
- 229960001674 tegafur Drugs 0.000 claims description 9
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 claims description 5
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 claims description 5
- 229950009822 gimeracil Drugs 0.000 claims description 5
- 229950000193 oteracil Drugs 0.000 claims description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 3
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims description 3
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- AZCCDRNDKZSNBW-UHFFFAOYSA-M [2-[bis(2-tetradecanoyloxyethyl)amino]-2-oxoethyl]-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC(=O)OCCN(C(=O)C[N+](C)(C)C)CCOC(=O)CCCCCCCCCCCCC AZCCDRNDKZSNBW-UHFFFAOYSA-M 0.000 claims description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 1
- 230000008685 targeting Effects 0.000 abstract description 34
- 238000000034 method Methods 0.000 abstract description 22
- 238000001727 in vivo Methods 0.000 abstract description 15
- 210000004027 cell Anatomy 0.000 description 52
- 201000011510 cancer Diseases 0.000 description 27
- 239000002479 lipoplex Substances 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 11
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000012737 fresh medium Substances 0.000 description 7
- 208000006178 malignant mesothelioma Diseases 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000013019 agitation Methods 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003327 cancerostatic effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000010409 thin film Substances 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 229940110282 alimta Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical group [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- BRVFNEZMTRVUGW-QFIPXVFZSA-N (2s)-2-[6-[(3-methyl-1-oxo-4h-benzo[f]quinazolin-9-yl)methylamino]-3-oxo-1h-isoindol-2-yl]pentanedioic acid Chemical compound C1=C2C(=O)N([C@@H](CCC(O)=O)C(O)=O)CC2=CC(NCC2=CC=C3C=CC4=C(C3=C2)C(=O)N=C(N4)C)=C1 BRVFNEZMTRVUGW-QFIPXVFZSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000000763 Survivin Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 201000009036 biliary tract cancer Diseases 0.000 description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 238000012969 post-insertion method Methods 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- DHMYGZIEILLVNR-UHFFFAOYSA-N 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione;1h-pyrimidine-2,4-dione Chemical compound O=C1C=CNC(=O)N1.O=C1NC(=O)C(F)=CN1C1OCCC1 DHMYGZIEILLVNR-UHFFFAOYSA-N 0.000 description 1
- NKGPJODWTZCHGF-UHFFFAOYSA-N 9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound OC1C(O)C(CO)OC1N1C(NC=NC2=S)=C2N=C1 NKGPJODWTZCHGF-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010051925 Intestinal adenocarcinoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- AFLXUQUGROGEFA-UHFFFAOYSA-N Nitrogen mustard N-oxide Chemical compound ClCC[N+]([O-])(C)CCCl AFLXUQUGROGEFA-UHFFFAOYSA-N 0.000 description 1
- 206010030081 Oculomucocutaneous syndrome Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- ORFPWVRKFLOQHK-UHFFFAOYSA-N amicarbazone Chemical compound CC(C)C1=NN(C(=O)NC(C)(C)C)C(=O)N1N ORFPWVRKFLOQHK-UHFFFAOYSA-N 0.000 description 1
- 235000019558 anosmia Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- YJTVZHOYBAOUTO-URBBEOKESA-N cytarabine ocfosfate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960000779 irinotecan hydrochloride Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Definitions
- the present invention relates to an antitumor agent comprising, as an active ingredient, a liposome containing a shRNA molecule targeting a thymidylate synthase and the use thereof.
- the present invention relates to the use of such antitumor agent in combination with a chemotherapeutic agent.
- RNAi molecules that cause RNA interference have been gaining attention as useful tools for treatment of tumors and the like.
- RNAi molecules that can inhibit tumor growth have been developed.
- the present inventors previously reported an RNAi molecule targeting thymidylate synthase (hereafter referred to as "TS”) involved in DNA synthesis.
- TS thymidylate synthase
- RNAi molecule remarkably inhibits TS expression and thus exhibits the antitumor effects, and that the RNAi molecule potentiates the antitumor effects of a 5-FU antitumor agent (and particularly a compound drug of tegafur, gimeracil, and oteracil potassium) ( W02010/113844 ).
- RNAi molecules quickly disintegrate upon in vivo administration. Therefore, it has been very difficult to deliver RNAi molecules at sufficient amounts for targeting tumors.
- RNAi molecule delivery methods are currently under development.
- a method comprising incorporating DNA encoding an RNAi molecule (and particularly an RNAi molecule having a short hairpin structure (shRNA)) into an adequate vector and administering the vector ( WO2010/113844 ).
- shRNA short hairpin structure
- it is necessary to directly inject the vector into a tumor for administration.
- an easier administration method e.g., intravenous administration
- RNAi molecules prepared by mixing an RNAi molecule with a liposome
- lipoplexes complexes prepared by mixing an RNAi molecule with a liposome
- Qixin Leng et al., Drug Future, 2009 September, 34(9), 721 Sherry Y. Wu et al., The AAPS Journal, Vol. 11, No. 4, December 2009 ; and B. Ozpolat et al., Journal of Internal Medicine 267; 44-53 2009 .
- lipoplexes upon repetitive administration of such lipoplexes, the lipoplexes are quickly trapped by the cells of immune systems of living bodies to which the lipoplexes have been administered. In such case, sufficient RNAi effects cannot be obtained. In addition, such administration can cause serious side effects, which is problematic.
- An object of the present invention is to provide a method for convenient and efficient in vivo delivery of shRNA targeting TS.
- the present inventors found that when shRNA capable of inhibiting TS expression is electrostatically bound to the surface of a PEG-modified cationic liposome, the shRNA bound to the liposome can be readily delivered to cancer cells.
- the present inventors found that when a PEG-modified cationic liposome to which shRNA has been bound is used in combination with a chemotherapeutic agent, and particularly, a 5-FU antitumor agent, cancer cell targetability can be enhanced, thereby allowing remarkably improving effects against cancer cells.
- the present inventors found that when a PEG-modified cationic liposome to which shRNA has been bound is used in combination with a chemotherapeutic agent having TS inhibitory action (e.g., a 5-FU antitumor agent or a pemetrexed sodium hydrate), sensitivity of cancer cells against the chemotherapeutic agent can be enhanced, thereby potentiating the antitumor effects.
- a chemotherapeutic agent having TS inhibitory action e.g., a 5-FU antitumor agent or a pemetrexed sodium hydrate
- the antitumor agent comprising, as an active ingredient, a liposome containing a shRNA molecule targeting a thymidylate synthase of the present invention can inhibit growth of TS-expressing tumors via in vivo administration.
- the short hairpin RNA (hereafter referred to as "shRNA”) capable of inhibiting expression of thymidylate synthase (hereafter referred to as "TS”) of the present invention exhibits TS-specific RNAi action when it targets an mRNA portion of thymidylate synthase. Accordingly, the short hairpin RNA can remarkably inhibit TS expression.
- TS thymidylate synthase
- Stringent conditions can be determined based on the melting temperature (Tm) for nucleic acid at which a hybrid is formed in accordance with a conventional method.
- washing conditions that allows maintenance of hybridization comprise, for example, generally "1 x SSC, 0.1% SDS, 37°C,” more strictly “0.5 x SSC, 0.1% SDS, 42°C,” and further strictly “0.1 x SSC, 0.1% SDS, 65°C.”
- the shRNA of the present invention comprises a sense strand having a nucleotide sequence of ORF encoding TS or a nucleotide sequence partially identical thereto and an antisense strand that hybridizes under stringent conditions to the sense strand.
- a nucleotide sequence of ORF or a nucleotide sequence partially identical thereto means a nucleotide sequence obtained by substituting thymine with uracil in the nucleotide sequence of ORF or a nucleotide sequence partially identical thereto.
- the sense strand consists of 15 to 25 nucleotides and preferably 19 nucleotides.
- the nucleotide sequence of the sense strand is desirably identical to the nucleotide sequence of ORF encoding TS. However, it may be a substantially identical (i.e., homologous) sequence.
- the nucleotide sequence of a sense strand may comprise the ORF nucleotide sequence including a substitution, a deletion, an insertion, and/or an addition of 1 or a plurarity of (i.e., 1 to 3) nucleotides, preferably 1 to 2 nucleotides, and more preferably 1 nucleotide.
- the antisense strand has a nucleotide sequence that can hybridize to the sense strand under stringent conditions.
- the antisense strand may comprise a mismatch, including a substitution, a deletion, an insertion, and/or an addition of 1 to 3 nucleotides, preferably 1 or 2 nucleotides, and more preferably 1 nucleotide as long as it can hybridize under stringent conditions.
- the antisense strand consists of a nucleotide sequence perfectly complementary to the sense strand.
- the nucleotide sequences of a sense strand and an antisense strand can be selected based on a known nucleotide sequence encoding TS (GenBank: CR601528.1). There are a variety of known methods for selecting such nucleotide sequences. For example, an siRNA Design Support System (Takara Bio Inc.) can be used.
- Examples of a sense strand used in the present invention include, but are not limited to, a sense strand consisting of any of the following nucleotide sequences: 5'-GUAACACCAUCGAUCAUGA-3' (SEQ ID NO: 1); 5'-GAAUACAGAGAUAUGGAAU-3' (SEQ ID NO: 3); 5'-CGAUCAUGAUGUAGAGUGU-3' (SEQ ID NO: 5); and 5'-GGGUGUUUUGGAGGAGUUGTT-3' (SEQ ID NO: 11).
- shRNA of the present invention comprises: a sense strand (5'-GUAACACCAUCGAUCAUGA-3'; SEQ ID NO: 1) and an antisense strand (5'-UCAUGAUCGAUGGUGUUAC-3'; SEQ ID NO: 2); a sense strand (5'-GAAUACAGAGAUAUGGAAU-3'; SEQ ID NO: 3) and an antisense strand (5'-AUUCCAUAUCUCUGUAUUC; SEQ ID NO: 4); a sense strand (5'-CGAUCAUGAUGUAGAGUGU-3'; SEQ ID NO: 5) and an antisense strand (5'-ACACUCUACAUCAUGAUCG-3'; SEQ ID NO: 6); or a sense strand (5'-GGGUGUUUUGGAGGAGUUGTT-3'; SEQ ID NO: 11) and an antisense strand (5'-AACAACUCCUCCAAAACACCC-3'; SEQ ID NO: 12).
- a sense strand 5'-GUAACACCA
- shRNA of the present invention comprises a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 1 and an antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 2.
- a sense strand and an antisense strand are linked via a linker portion.
- the linker portion forms a loop such that the resulting strand is folded. Accordingly, the antisense strand and the sense strand hybridize to each other, resulting in formation of a double strand.
- a linker portion contained in a shRNA molecule is not particularly limited and thus it may be a polynucleotide linker or a non-polynucleotide linker as long as it links a sense strand and an antisense strand so as to form a stem loop structure.
- a polynucleotide linker is the same consisiting of 2 to 22 nucleotides known in the art.
- UAGUGCUCCUGGUUG SEQ ID NO: 7
- UUCAAGAGA CCACC
- CUCGAG CCACACC
- UUCAAGAGA AUG, CCC
- UUCG UAGUGCUCCUGGUUG
- shRNA of the present invention has an overhang comprising at least 2 nucleotides at the 3' end.
- the term "overhang” refers to a nucleotide added at the 3' end of an antisense strand that does not have a nucleotide capable of complementarily binding at a position corresponding to a sense strand. If an antisense strand does not have an overhang at the 3' end, the degree of TS expression inhibition caused by shRNA decreases by approximately 40% to 60% upon transfection with the use of a PEG-modified cationic liposome described in detail below, compared with a case in which an antisense strand has an overhang at the 3' end. Types or numbers of nucleotides of the overhang are not limited.
- such overhand consists of a sequence comprising 1 to 5 nucleotides, preferably 1 to 3 nucleotides, and more preferably 1 or 2 nucleotides.
- a sequence include TTT, UU, and TT.
- UU is used.
- shRNA is a single strand RNA consisting of the nucleotide sequence shown in SEQ ID NO: 8.
- a sense strand or an antisense strand may be phosphorylated at the 5' end according to need.
- Triphosphoric acid (ppp) may be bound to the 5' end.
- PEG-modified cationic liposome of the present invention one or a plurality of polyethyleneglycol (PEG) molecules are covalently bound to the cationic liposome surface, allowing the cationic liposome to have improved ability to circulate in vivo.
- PEG polyethyleneglycol
- the cationic liposome can be produced by a known method, such as a thin film shaking method (the Bangham method) ( A. D. Bangham et al., J. Mol. Biol., 13, 238-252 (1965 ); A. D. Bangham and R. W. Horne, J. Mol. Biol., 8, 660-668 (1964 )).
- a thin film shaking method the Bangham method
- a phospholipid is dissolved in an organic solvent such as chloroform in a container such as a flask.
- the organic solvent is evaporated to form a lipid membrane on the bottom of the container.
- An aqueous solution such as buffer is introduced thereinto, followed by agitation.
- a suspension containing liposomes can be obtained.
- the cationic liposome of the present invention has uni- or multi-lamellar membranes consisting of at least one phospholipid selected from the group consisting of dioleoylphosphatidylethanolamine (hereafter referred to as "DOPE”), palmitoyloleoylglycerophosphocholine (hereafter referred to as "POPC”), cholesterol (hereafter referred to as "CHOL”) O,O'-ditetradecanoyl-N-( ⁇ -trimethylammonioacetyl)diethanolaminechloride (hereafter referred to as "DC-6-14”), hydrogenated purified yolk phosphatidylcholine, hydrogenated purified soybean phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, and 1-palmitoyl-2-oleoyl phosphatidylcholine.
- DOPE dioleoylphosphatidylethanolamine
- the cationic liposome of the present invention consisits of DOPE, POPC, CHOL, and DC-6-14.
- a PEG molecule bound to the cationic liposome surface is selected from PEG molecules having molecular weights of 500 to 5000 and preferably approximately 2000. Binding of PEG to a cationic liposome can be carried out by a known method which is not particularly limited. However, a post insertion method or the like can be used. Specifically, after formation of the cationic liposome, a PEGylated phospholipid is incubated with the cationic liposome under appropriate conditions (e.g., 30°C to 60°C for 30 minutes to 3 hours).
- the lipid portion of the PEGylated phospholipid can be incorporated into the outer phospholipid membrane of the cationic liposome in a manner such that PEG is exposed on the cationic liposome surface.
- the amount of the PEGylated phospholipid used for the incorporation accounts for 3% to 10% and preferably 5% (molar percentage) of the total lipid amount of the cationic liposome.
- the PEGylated phospholipid that can be used according to the present invention include, but are not limited to, mPEG 2000 -DSPE.
- the PEG-modified cationic liposome of the present invention has a particle size of 80 to 200 nm and preferably approximately 100 nm.
- the PEG-modified cationic liposome of the present invention has a zeta potential of 10 to 40 mV and preferably approximately 25 mV.
- the above shRNA is covalently or noncovalently bound to the membrane surface of the PEG-modified cationic liposome.
- agitation allows uniform dispersion of the shRNA on the surface of PEG-modified cationic liposome at binding. Therefore, it is possible to prevent irregular tissue distribution of the PEG-modified cationic liposome due to nonuniform binding of shRNA on the liposome.
- the PEG-modified cationic liposome containing shRNA has a particle size of 120 to 600 nm and preferably 200 to 300 nm.
- the PEG-modified cationic liposome containing shRNA has a zeta potential of 5 to 30 mV and preferably approximately 10 to 25 mV according to the present invention.
- the surface charge of the PEG-modified cationic liposome containing shRNA is close to neutral.
- the PEG-modified cationic liposome containing shRNA is unlikely to bind to a serum protein due to PEG-induced steric hindrance. Therefore, the liposome can be prevented from being trapped in lung alveoli, allowing the liposome to have improved ability to circulate in vivo.
- the PEG-modified cationic liposome containing shRNA of the present invention may contain further shRNA or siRNA targeting a different gene expressed in tumor cells, in addition to the above shRNA.
- a different gene expressed in tumor cells include, but are not limited to, genes encoding factors involved in tumor cell proliferation, for example, the growth regulatory factor group (consisting of VEGF, EGFR, PDGF, HGF, Wint, Bcl-2, survivin, and the like) and the nucleotide synthesis-related enzyme group (consisting of ribonucleotide reductase, DNA polymerase, and the like).
- the above shRNA and the siRNA or sh RNA targeting a different gene expressed in tumor cells may be bound to an identical PEG-modified cationic liposome or they may be separately bound to different PEG-modified cationic liposomes.
- PEG-modified cationic liposome containing shRNA is sometimes referred to as "PEG-modified lipoplex.”
- the PEG-modified cationic liposome containing shRNA can be used as an antitumor agent for treating cancer.
- Cancers exhibiting high TS expression levels can be treated with the antitumor agent of the present invention.
- examples of such cancers include, but are not particularly limited to, colorectal cancer, liver cancer, kidney cancer, head and neck cancer, esophageal cancer, gastric cancer, biliary tract cancer, gallbladder and bile duct cancer, pancreatic cancer, lung cancer, mammary cancer, ovarian cancer, cervical cancer, uterine body cancer, bladder cancer, prostate cancer, testicular tumor, osteogenic and soft-tissue sarcomas, leukaemia, malignant lymphoma, multiple myeloma, skin cancer, brain tumor and plura malignant mesothelioma.
- colorectal cancer gastric cancer, head and neck cancer, lung cancer, mammary cancer, pancreatic cancer, biliary tract cancer, liver cancer and plura malignant mesothelioma.
- colorectal cancer and plura malignant mesothelioma are particularly preferable.
- the antitumor agent of the present invention may contain additives that can be used for production of medicines, in addition to the PEG-modified cationic liposome containing shRNA.
- additives include excipients, binders, disintegrators, lubricants, diluents, solubilizers, suspending agents, isotonizing agents, pH modifiers, buffers, stabilizers, colorants, flavoring agents, corrigents, and histidine.
- excipients include lactose, sucrose, sodium chloride, glucose, maltose, mannitol, erythritol, xylitol, maltitol, inositol, dextran, sorbitol, albumin, urea, starch, calcium carbonate, kaoline, crystalline cellulose, silica, methylcellulose, glycerine, sodium alginate, gum Arabic, and a mixture of any thereof.
- lubricants include purified talc, stearate, sodium borate, polyethylene glycol, and a mixture of any thereof.
- binders include simple syrup, glucose solution, starch solution, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, carboxymethyl cellulose, shellac, methylcellulose, ethyl cellulose, water, ethanol, potassium phosphate, and a mixture of any thereof.
- disintegrators include dry starch, sodium alginate, agar powder, laminaran powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose, and a mixture of any thereof.
- diluents include water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, and a mixture of any thereof.
- stabilizers include sodium pyrosulfife, ethylenediaminetetraacetic acid, thioglycolic acid, thiolactic acid, and a mixture of any thereof.
- isotonizing agents include sodium chloride, boric acid, glucose, glycerine, and a mixture of any thereof.
- pH modifiers and buffers include sodium citrate, citric acid, sodium acetate, sodium phosphate, and a mixture of any thereof.
- the antitumor agent of the present invention can be administered through an oral or parenteral route (e.g., intravenous administration, intraarterial administration, topical administration via injection, intraperitoneal or intrathoracic administration, subcutaneous administration, intramuscular administration, sublingual administration, percutaneous absorption, or intrarectal administration).
- an oral or parenteral route e.g., intravenous administration, intraarterial administration, topical administration via injection, intraperitoneal or intrathoracic administration, subcutaneous administration, intramuscular administration, sublingual administration, percutaneous absorption, or intrarectal administration.
- the antitumor agent of the present invention can be administered via intravenous administration, intraperitoneal administration, or intrathoracic administration.
- the antitumor agent of the present invention can be prepared in an adequate dosage form in accordance with the route of administration.
- the antitumor agent can be prepared in various dosage forms, such as injection preparations, suspensions, emulsifiers, ointments, creams, tablets, capsules, granule preparations, powder preparations, pills, fine grains, troches, drug preparations for intrarectal administration, oleagenous suppositories, or water-soluble suppositories.
- Effects of the antitumor agent of the present invention can be evaluated by administering the antitumor agent to cells or tissues from the above cancer or individuals who have contracted the cancer, comparing the tumor sizes with the cellular or tissue tumor sizes from the above cancer or individuals who have contracted the cancer to which the antitumor agent has not been administered (or prior to administration), and confirming whether or not tumor shrinkage or disappearance can be observed.
- Cancer cells used for evaluation of effects of the antitumor agent of the present invention are not limited to a particular type of cancer cells, as long as TS is expressed in the cells.
- cancer cells used for evaluation of effects of the antitumor agent of the present invention include: human colorectal cancer cell lines such as DLD-1, DLD-1/5FU (a 5-FU-resistant DLD-1 cell line), KM12C/5FU (a 5-FU-resistant KM12C cell line), and HT29/5FU (a 5-FU-resistant HT29 cell line); and a human gastric cancer cell line such as NUGC-3/5FU (a 5-FU-resistant NUGC-3 cell line) ; and a human mesothelioma cell line (METO 211 H).
- human colorectal cancer cell lines such as DLD-1, DLD-1/5FU (a 5-FU-resistant DLD-1 cell line), KM12C/5FU (a 5-FU-resistant KM12C cell line), and HT29/5FU (a 5-FU-resistant HT29 cell line)
- a human gastric cancer cell line such as NUGC-3/5FU (a 5-FU-resistant NUGC-3 cell line)
- a human mesothelioma cell line
- the antitumor agent of the present invention is capable of exerting antitumor effects that are two, three, four, five, ten, twenty, thirty, forty, fifty, one hundred, or more times as great as an antitumor agent comprising RNAi molecule targeting TS mRNA as an active ingredient, which is known in the art.
- a viral vector containing DNA encoding shRNA has been conventionally used for in vivo delivery of shRNA to target cells ( WO2010/113844 ).
- the DNA encoding shRNA is transferred into cells by making use of water pressure upon injection of the viral vector or viral infection, resulting in intranuclear expression of shRNA.
- the expressed shRNA comes into contact with an enzyme called "dicer" such that the stem loop construct is cleaved therefrom.
- siRNA consisting of a double strand RNA (consisting of strands complementary to each other) is formed such that RNAi action is exhibited.
- shRNA complexed with a PEG-modified cationic liposome in the agent is delivered to tumor cells.
- shRNA delivered to tumor cells is transferred to the insides of cells via endocytosis.
- shRNA of the present invention is not shRNA expressed in target cells. The present inventors found for the first time that exogenous shRNA introduced extracellularly in vivo can exhibit RNAi action without being degraded and thus it can inhibit expression of an endogenous gene expressed in target cells.
- siRNA is coupled to a PEG-modified cationic liposome
- a sense strand or antisense strand alone of siRNA that does not form a double strand (consisting of strands complementary to each other) would bind to the PEG-modified cationic liposome during the manufacturing process.
- Such PEG-modified cationic liposome containing only a sense strand or antisense strand of siRNA can be regarded as an impurity and therefore such liposome is an undesirable pharmacological product.
- PEG-modified cationic liposome containing shRNA such impurity is unlikely to be formed and thus the liposome can be a desirable pharmacological product.
- the antitumor agent of the present invention can be used with an existing chemotherapeutic agent.
- an existing chemotherapeutic agent include an antitumor agent having TS inhibitory action.
- Such "antitumor agent having TS inhibitory action” is not particularly limited as long as it can inhibit the function of TS.
- Examples thereof include 5-FU antitumor agents, pemetrexed sodium hydrate, raltitrexed (Tomudex), methotrexate (MTX), and OSI-7904L (OSI).
- TS expression level The relationship between the TS expression level and the sensitivity of a 5-FU antitumor agent has been reported ( Patrick G. Johnston et al., Cancer Res 1995; 55: 1407-12 and Kun-Huei Yeh et al., Cancer 1998; 82: 1626-31 ).
- 5-FU antitumor agents are remarkably effective for cancer patients with relatively low TS expression levels, while on the other hand, cancer patients with relatively high TS expression levels have resistance to 5-FU antitumor agents.
- Administraton of the antitumor agent of the present invention enables suppression of TS production in tumor tissue, allowing an increase in the sensitivity of a 5-FU antitumor agent in such tumor tissue.
- the PEG-modified cationic liposome is selectively accumulated in tumors when used in combination with a 5-FU antitumor agent ( Yusuke Doi et al., Cancer Sci, November, 2010, vol. 101, no. 11, 2470-2475 ).
- the antitumor agent of the present invention containing the PEG-modified cationic liposome When used in combination with a 5-FU antitumor agent, the agent has the above effects and thus shRNA can be delivered to tumors with good efficienty.
- the antitumor agent of the present invention is capable of exerting antitumor effects that are two, three, four, five, or more times as great as a 5-FU antitumor agent or the antitumor agent of the present invention used alone.
- Examples of 5-FU antitumor agents include 5-FU and a 5-FU derivative from which 5-FU is produced as an active metabolite.
- An example of a 5-FU derivative is an agent containing tegafur.
- a 5-FU derivative is preferably a compound drug containing tegafur. Specific examples thereof include a compound drug of tegafur and uracil (e.g., UFT (registered trademark) (Taiho Phamaceutical Co., Ltd.)), a compound drug of tegafur, gimeracil, and oteracil potassium.
- TS-1 registered trademark
- Taiho Phamaceutical Co., Ltd. The compound drug of tegafur, gimeracil, and oteracil potassium (e.g., TS-1 (registered trademark), Taiho Phamaceutical Co., Ltd.) described below is particularly preferable.
- 5-FU antitumor agent is herein referred to as "S-1,” or "TS-1.”
- S-1 5-FU antitumor agent
- pemetrexed sodium hydrate is Alimta (registered trademark) (Eli Lilly Japan K.K.).
- shRNA can be efficiently delivered to tumors when pemetrexed sodium hydrate and the antitumor agent of the present invention are used in combination.
- a combination use of pemetrexed sodium hydrate and the antitumor agent of the present invention results in remarkably significant antitumor effects that are two, three, four, five, or more times as great as the those of pemetrexed sodium hydrate or the antitumor agent of the present invention used alone.
- the antitumor agent of the present invention can be used in combination with a different existing chemotherapeutic agent in addition to or instead of the antitumor agent having TS inhibitory action.
- chemotherapeutic agent include cyclophosphamide, nitrogen mustard N-oxide, ifosfamide, melphalan, busulphan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine, temozolomide, carmustine, pemetrexed disodium, methotrexate, 6-mercaptopurine riboside, mercaptopurine, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, gemcitabine, fludarabine, pemetrexed, cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, irinotecan hydrochloride
- chemotherapeutic agents selected from the examples can be used.
- shRNA can be efficiently delivered to tumors when the above chemotherapeutic agent and the antitumor agent of the present invention are used in combination.
- the combination use of the chemotherapeutic agent and the antitumor agent of the present invention results in remarkably significant antitumor effects two, three, four, five, or more times as great as the chemotherapeutic agent or the antitumor agent of the present invention used alone.
- a combined product of the antitumor agent of the present invention and an existing chemotherapeutic agent can be provided as long as the antitumor agent of the present invention and the existing chemotherapeutic agent are administered in combination.
- Such “combined product” may be a compound drug containing the antitumor agent of the present invention and the existing chemotherapeutic agent as active ingredients.
- a single package (a formulation kit) containing the antitumor agent of the present invention and the existing chemotherapeutic agent appropriate for combined administration can be produced/packaged/distributed.
- combined administration can be referred to not only simultaneous administration of the antitumor agent of the present invention and the existing chemotherapeutic agent but also administration of the antitumor agent of the present invention and the existing chemotherapeutic agent at certain intervals.
- the administration dose and the administration frequency of the antitumor agent of the present invention can vary depending on factors such as patient age and weight, and severity of disease.
- the antitumor agent of the present invention can be administered at a single dose appropriately within the range of 0.0001 mg to 100 mg in terms of shRNA per kg body weight 1 to 3 times every day or every 1 to 21 days.
- the PEG-modified cationic liposome containing shRNA contained in the antitumor agent of the present invention has greater ability to circulate in vivo than a conventionally known complex (lipoplex) comprising an RNAi molecule and a liposome. Therefore, it is possible to avoid frequent administration. Such administration allows avoidance of in vivo foreign body detection by the immune system.
- the administration dose and the administration frequency of the existing chemotherapeutic agent can vary depending on factors such as types of chemical substances contained as active ingredients, patient age and weight, and severity of disease.
- the existing chemotherapeutic agent can be administered at a single dose appropriately within the range of 0.0001 mg to 1000 mg per kg body weight 1 to 3 times every day or every 1 to 14 days.
- the existing chemotherapeutic agent is a 5-FU antitumor agent, it can be administered at a daily dose of 60 to 160 mg in terms of tegafur every day or every 1 to 7 days.
- the existing chemotherapeutic agent can be administered at lower doses and frequencies when used in combination with the antitumor agent of the present invention compared with a case in which it is administered alone.
- side effects include, but are not limited to, bone-marrow suppression, hemolytic anemia, disseminated intravascular coagulation syndrome, fulminant hepatic failure, dehydration, enteritis, interstitial pneumonia, stomatitis, gastrointestinal tract ulcer, gastrointestinal tract hemorrhage, perforation of the gastrointestinal tract, acute renal failure, muco-cutaneo-ocular syndrome, toxic epidermal necrolysis, psychoneurotic disorder, acute pancreatitis, rhabdomyolysis, and anosmia.
- the present invention also relates to a method for treating cancer using the antitumor agent of the present invention.
- cancers treatable by the method include the cancers defined above.
- the administration routes and the dosages of the antitumor agent of the present invention and the existing chemotherapeutic agents are as described above.
- siRNA and shRNA described below were synthesized by a conventionally known method.
- siRNA targeting TS used herein is syntheseized as the siRNA targeting TS that has been confirmed to have the antitumor effects ( W02010/113844 ). It comprises the sense strand and the antisense strand shown below.
- siRNA targeting TS is hereafter referred to as "siTS.”
- siRNA targeting luciferase was synthesized as control siRNA.
- the siRNA comprises the sense strand and the antisense strand shown below.
- siRNA targeting luciferase is hereafter referred to as "siCont.”
- shRNA targeting TS used herein is syntheseized as the shRNA targeting TS that has been confirmed to have the antitumor effects ( W02010/113844 ) It comprises the following sequence.
- TS-shRNA
- shRNA targeting TS is hereafter referred to as "shTS.”
- Example 2 siRNA and shRNA-induced TS expression inhibition
- LipofectamineTM RNAi MAX (hereafter referred to as "Lf RNAi MAX"), which is a cationic liposome, was used as a transfection reagent.
- shRNA or siRNA prepared in Example 1 and Lf RNAi MAX were separately diluted with OptiMEM.
- the resulting solutions were mixed at a ratio of shRNA or siRNA to Lf RNAi MAX of 100 (pmol) : 5 ( ⁇ L).
- equivalent amounts of the shRNA or siRNA solution and the Lf RNAi MAX solution were used.
- the obtained liquid mixture was left at room temperature for 10 to 20 minutes, resulting in complex (lipoplex) formation.
- Each lipoplex was directly added to a 10-cm dish containing OptiMEM to adjust the total volume to 5 ml.
- DLD-1 or DLD-1/FU cell suspension (10 ml) was seeded on the dish (500,000 cells/dish) so as to result in a final total volume of 15 ml, followed by transfection.
- the final concentration of shRNA or siRNA was adjusted to 1, 5, or 10 nM.
- culture was carried out in a medium at 37°C under 5% CO 2 for 72 hours. Then, the cell extract was prepared by the method described below.
- the sample (6 ⁇ L corresponding to 9 ⁇ g of protein/lane) was applied to gel.
- Such gel was connected to a power supply (Bio-Rad laboratories), and electrophoresis was performed for approximately 80 minutes at a constant current of 40 mA for two gel sheets (20 mA for a single gel sheet).
- Hybond-ECL Filter paper cut in pieces with adequate sizes and Hybond-ECL were immersed in blotting buffer for pretreatment. After SDS-PAGE, a transfer apparatus was used for transferring protein to Hybond-ECL. Hybond-ECL subjected to transfer was immersed in blocking buffer (5% skim milk) for blocking at room temperature for 1 hour and washed 3 times (5 minutes each) with Tween buffer.
- blocking buffer 5% skim milk
- TS and ⁇ -actin For detection of TS and ⁇ -actin, overnight reaction was carried out at 4°C using the following primary antibodies each diluted with Tween buffer: a mouse monoclonal anti-human TS antibody (1:1000) (ANASPEC, Inc., CA, USA); and a mouse monoclonal anti-human ⁇ -actin antibody (1:500) (Bio Vision, Inc., CA, USA). Washing with Tween buffer was conducted 3 times (5 minutes each). Then, reaction was carried out at room temperature for 1 hour using a secondary antibody (an HRP-conjugated goat anti-mouse secondary antibody (1:2000) (MP Biomedicals, LLC, Japan)) solution diluted with Tween buffer. Washing with Tween buffer was conducted 3 times (5 minutes each), followed by a reaction with an ECL chemiluminescence reagent for approximately 1 minute. The band of each protein of interest was detected on X-ray film.
- Fig. 1 shows the results.
- Example 3 Cancer cell (Human colorectal cancer cell) proliferation inhibitory effects of siRNA and shRNA
- experimentaion was performed on a 96-well plate scale.
- a lipoplex obtained as in the case of Example 2 was directly added to wells containing OptiMEM to adjust the total volume to 50 ⁇ l per well.
- a DLD-1 or DLD-1/FU cell (human colonic intestinal adenocarcinoma cell) suspension (2,000 cells/100 ⁇ l) was added to the wells to which the lipoplex had been added (final total volume: 150 ⁇ l), followed by transfection.
- the final concentration of shRNA or siRNA per well was 5 nM.
- the medium was removed from each well 24 hours after the initiation of transfection.
- a fresh medium containing or not containing an existing chemotherapeutic agent, 5-FU was added thereto (200 ⁇ l per well).
- 5-FU was added to DLD-1 so as to result in a concentration of 0.1 ⁇ g/mL.
- 5-FU was added to DLD-1/FU so as to result in a concentration of 10 ⁇ g/mL.
- the medium was removed 0, 24, 48, 72, or 96 hours after the addition of the fresh medium.
- a 0.5% MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) solution was added thereto (50 ⁇ L per well), followed by incubation at 37°C under 5% CO 2 for 4 hours. Also, the 0.5% MTT solution was added to cell-free wells to obtain a background absorbance.
- Cell proliferation rate (%) [A570 (X hours after the addition of fresh medium)/A570 (0 hours after the addition of fresh medium)] x 100
- Figs. 2 and 3 show the results.
- siTS and shTS were found to have significantly inhibited proliferation of DLD-1 cells and DLD-1/FU cells in the presence of 5-FU.
- Cationic liposome was prepared using the Bangham method.
- Cationic lipids i.e., DOPE, POPC, CHOL, and DC-6-14
- DOPE DOPE
- POPC POPC
- CHOL CHOL
- DC-6-14 3:2:3:2 (molar ratio).
- the samples were introduced into a plugged test tube and mixed therein (the total lipid amount: 150 mmol).
- chloroform was removed therefrom under reduced pressure using a rotary evapolator (IWAKI, Tokyo). Subsequently, the test tube was placed overnight in a vacuum pump for complete removal of chloroform.
- a lipid thin film was formed in the test tube.
- a 9% sucrose solution (30 mL, pH 7.4) was added as an internal water phase to the lipid thin film, followed by intensive agitation at 37°C.
- MLVs multilamellar vesicles
- final lipid concentration: 50 mM final lipid concentration: 50 mM.
- the obtained solution was heated to 37°C, during which LUVs (large unilamellar vesicles) having particle sizes of approximately 100 nm were prepared using 200-, 100-, and 50-nm polycarbonate membranes (Nucleopore, CA, USA) by an extrusion method.
- the particle sizes and zeta potentials of the liposomes were determied using an NICOMP 370 (Particle Sizing System, CA, USA) (with a dinamic light scattering method and an electrophoresis light scattering method, respectively).
- the average particle size was found to be 119.9 nm and the zeta potential was found to be 25.56 mV for the prepared liposomes.
- the liposomes were PEGylated by a post insertion method.
- the liposome solution was prepared.
- a 9% sucrose solution in which mPEG 2000 -DSPE had been completely dissolved was added to the liposome solution such that the molar percentage of mPEG 2000 -DSPE accounted for 5% of the total amount of lipids (DOPE, POPC, CHOL, and DC-6-14), followed by mild shaking in an incubator provided with a shaker at 37°C for 1 hour.
- the average particle size and zeta potential for the prepared PEG-modified lipoplex were found to be 286.8 nm and 15.81 mV, respectively.
- mice were subcutaneously inoculated with a DLD-1 cell suspension (2 x 10 6 cells/100 ⁇ L). On Day 8 from tumor cell inoculation, mice with tumor volumes of 50-100 mm 3 were subjected to an in vivo experiment.
- the PEG-modified lipoplex was administered via the mouse caudal vein to the DLD-1 tumor-bearing mice at a dose of 80 ⁇ g/300 ⁇ L (in terms of the shRNA amount) at 1-day intervals for 8 times in total starting on day 8 after tumor transplantation.
- TS-1 Taiho Phamaceutical Co., Ltd.
- the agent was orally administered every day for 15 days at a dose of 6.9 mg (tegafur)/kg starting on day 8 after tumor transplantation.
- Carcinostatic activity was examined based on changes in tumor volume and body weight.
- Tumor volume mm 3 long diameter of tumor x short diameter of tumor 2 x 0.5
- Figs. 4 and 5 show the results.
- Example 7 Cancer cell (Human plura malignant mesothelioma cell) proliferation inhibitory effects of shRNA
- the experiment was carried out according to the method described in Example 3, except for using human plura malignant mesothelioma cell line (MSTO 211H) instead of human colorectal carcinoma cell line (DLD-1 or DLD-1/FU) and using pemetrexed sodium hydrate (Alimta (registered trademark) (Eli Lilly Japan K.K.)) instead of 5-FU as an exsisting chemotherapeutic agent.
- MSTO 211H human plura malignant mesothelioma cell line
- DLD-1 or DLD-1/FU human colorectal carcinoma cell line
- pemetrexed sodium hydrate Aligna (registered trademark) (Eli Lilly Japan K.K.)
- shTS significantly inhibited proliferation of MSTO 211H cells in the presence of pemetrexed sodium hydrate.
- Example 8 Antitumor effects of PEG-modified lipoplex upon systemic administration to MSTO 211H cancer-bearing mouse MSTO 211H cancer-bearing mouse production
- mice were subcutaneously inoculated with a MSTO 211H cell suspension (5 x 10 6 cells/100 ⁇ L). On day 14 from tumor cell inoculation, mice with tumor volumes of 50-100 mm 3 were subjected to an in vivo experiment.
- the PEG-modified lipoplex prepared in Example 5 was administered via the mouse caudal vein to the MSTO 211H tumor bearing mice at a dose of 40 ⁇ g/200 ⁇ L (in terms of the shRNA amount) at 1-day intervals for 6 times in total starting on day 14 after tumor transplantation.
- the existing chemotherapeutic agent pemetrexed sodium hydrate (Alimta (registered trademark) (Eli Lilly Japan K.K.)
- the agent was intraperitoneally administered 6 times in total (day 1, 2, 3, 8, 9 and 10) with 100 mg/kg starting on day 14 after tumor transplantation.
- TGI tumor growth inhibition rate
- Figs. 7 shows the result.
- Proliferation of TS-expressing tumor can be inhibited via in vivo administration of the antitumor agent containing, as an active ingredient, a liposome containing a shRNA molecule targeting a thymidylate synthase of the present invention. Further, if the antitumor agent is used in combination with a chemotherapeutic agent, cancer tissue targetability is promoted and thus the antitumor effects can be remarkably improved. It is expected that the present invention will contribute to the field of cancer therapy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present invention relates to an antitumor agent comprising, as an active ingredient, a liposome containing a shRNA molecule targeting a thymidylate synthase and the use thereof. In particular, the present invention relates to the use of such antitumor agent in combination with a chemotherapeutic agent.
- In recent years, RNAi molecules that cause RNA interference (hereafter referred to as "RNAi") have been gaining attention as useful tools for treatment of tumors and the like. A variety of RNAi molecules that can inhibit tumor growth have been developed. The present inventors previously reported an RNAi molecule targeting thymidylate synthase (hereafter referred to as "TS") involved in DNA synthesis. In addition, the present inventors reported that the RNAi molecule remarkably inhibits TS expression and thus exhibits the antitumor effects, and that the RNAi molecule potentiates the antitumor effects of a 5-FU antitumor agent (and particularly a compound drug of tegafur, gimeracil, and oteracil potassium) (
W02010/113844 ). - However, in general, RNAi molecules quickly disintegrate upon in vivo administration. Therefore, it has been very difficult to deliver RNAi molecules at sufficient amounts for targeting tumors.
- In order to solve the above problems, a variety of RNAi molecule delivery methods are currently under development. For example, there is a method comprising incorporating DNA encoding an RNAi molecule (and particularly an RNAi molecule having a short hairpin structure (shRNA)) into an adequate vector and administering the vector (
WO2010/113844 ). However, according to this method, it is necessary to directly inject the vector into a tumor for administration. In view of clinical application, an easier administration method (e.g., intravenous administration) has been awaited. In addition, methods for deliverying RNAi molecules to tumor cells using complexes (lipoplexes) prepared by mixing an RNAi molecule with a liposome have been developed (Qixin Leng et al., Drug Future, 2009 September, 34(9), 721; Sherry Y. Wu et al., The AAPS Journal, Vol. 11, No. 4, December 2009; and B. Ozpolat et al., Journal of Internal Medicine 267; 44-53 2009). However, upon repetitive administration of such lipoplexes, the lipoplexes are quickly trapped by the cells of immune systems of living bodies to which the lipoplexes have been administered. In such case, sufficient RNAi effects cannot be obtained. In addition, such administration can cause serious side effects, which is problematic. - Therefore, a method for efficiently deliverying RNAi molecules to tumors via in vivo administration still has been awaited in the art.
- An object of the present invention is to provide a method for convenient and efficient in vivo delivery of shRNA targeting TS.
- As a result of intensive studies in order to solve the above problems, the present inventors found that when shRNA capable of inhibiting TS expression is electrostatically bound to the surface of a PEG-modified cationic liposome, the shRNA bound to the liposome can be readily delivered to cancer cells. In addition, the present inventors found that when a PEG-modified cationic liposome to which shRNA has been bound is used in combination with a chemotherapeutic agent, and particularly, a 5-FU antitumor agent, cancer cell targetability can be enhanced, thereby allowing remarkably improving effects against cancer cells. Further, the present inventors found that when a PEG-modified cationic liposome to which shRNA has been bound is used in combination with a chemotherapeutic agent having TS inhibitory action (e.g., a 5-FU antitumor agent or a pemetrexed sodium hydrate), sensitivity of cancer cells against the chemotherapeutic agent can be enhanced, thereby potentiating the antitumor effects. The present invention has been made based on the above findings.
- Specifically, the present invention is described as follows.
- [1] An antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3' end.
- [2] The antitumor agent according to [1], wherein the shRNA comprises a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 1 and an antisense strand that hybridizes under stringent conditions to the sense strand.
- [3] The antitumor agent according to [1] or [2], wherein the shRNA comprises a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 1 and an antisense strand consisitng of the nucleotide sequence shown in SEQ ID NO: 2.
- [4] The antitumor agent according to any one of [1] to [3], wherein the shRNA consists of the nucleotide sequence shown in SEQ ID NO: 8.
- [5] The antitumor agent according to any one of [1] to [4], wherein the PEG-modified cationic liposome comprises a cationic liposome composed of dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylglycerophosphocholine (POPC), cholesterol (CHOL), and O,O'-ditetradecanoyl-N-(α-trimethylammonioacetyl)diethanolaminechloride (DC-6-14).
- [6] The antitumor agent according to [5], which contains DOPE, POPC, CHOL, and DC-6-14 at a molar ratio of 3:2:3:2.
- [7] The antitumor agent according to any one of [1] to [6], wherein the particle size of the antitumor agent is 200 to 300 nm.
- [8] The antitumor agent according to any one of [1] to [7], wherein further siRNA or shRNA capable of inhibiting expression of a gene selected from the group consisting of genes involved in tumor cell proliferation is bound to the surface of the PEG-modified cationic liposome.
- [9] The antitumor agent according to [8], wherein the gene involved in tumor cell proliferation is at least one gene selected from the group consisting of genes encoding VEGF, EGFR, PDGF, HGF, Wint, Bcl-2, survivin, ribonucleotide reductase, and DNA polymerase.
- [10] The antitumor agent according to any one of [1] to [9], which is used in combination with a chemotherapeutic agent for treating tumors.
- [11] A combined product, which contains the antitumor agent according to any one of [1] to [10] and a chemotherapeutic agent for treating tumors.
- [12] The antitumor agent according to [10] or the combined product according to [11], wherein the chemotherapeutic agent for treating tumors is an antitumor agent having TS inhibitory action.
- [13] The antitumor agent or the combined product according to [12], wherein the antitumor agent having TS inhibitory action is a 5-FU antitumor agent or a pemetrexed sodium hydrate.
- [14] The antitumor agent or the combined product according to [13], wherein the 5-FU antitumor agent is a compound drug of tegafur, gimeracil, and oteracil potassium.
- This description includes part or all of the contents as disclosed in the description and/or drawings of Japanese Patent Application No.
2011-114946 - The antitumor agent comprising, as an active ingredient, a liposome containing a shRNA molecule targeting a thymidylate synthase of the present invention can inhibit growth of TS-expressing tumors via in vivo administration.
-
-
Fig. 1 shows a characteristic image indicating TS expression inhibitory effects of siRNA and shRNA targeting TS for human colorectal cancer cell lines (DLD-1(A) and DLD-1/FU(B)). Each lane shows the results for the following samples treated with siRNA or shRNA: 1: Untreated; 2: 10 nM siCont; 3: 1 nM siTS; 4: 5 nM siTS; 5: 10 nM siTS; 6: 1 nM shTS; 7: 5 nM shTS; and 8: 10 nM shTS. -
Fig. 2(A) and 2(B) each show a characteristic chart indicating TS expression inhibitory effects on cell growth for (A): siRNA targeting TS; and (B): shRNA targeting TS confirmed in a human colorectal cancer cell line (DLD-1) under the presence or absence of 5-FU.Fig. 2 (C) shows the cell growth inhibitory rate (%) for eachsample 96 hours after the addition of fresh medium. -
Fig. 3(A) and 3(B) each show a characteristic chart indicating TS expression inhibitory effects on cell growth for (A): siRNA targeting TS; and (B): shRNA targeting TS confirmed in a human colorectal cancer cell line (DLD-1/FU) under the presence or absence of 5-FU.Fig. 3 (C) shows the cell growth inhibitory rate (%) for eachsample 96 hours after the addition of fresh medium. -
Figs. 4(A) and 4(B) each show a characteristic chart indicating results confirmed for shRNA targeting TS under the presence or absence of S-1 in mice bearing a human colorectal cancer cell line (DLD-1) ((A): tumor growth inhibitory effects; and (B): weight increase or decrease). -
Fig. 5 shows a photo indicating tumor growth inhibitory effects confirmed for shRNA targeting TS under the presence or absence of TS-1 in mice bearing a human colorectal cancer cell line (DLD-1): 1: Control (sucrose administration); 2: S-1; 3: TS-shRNA/liposome; and 4: S-1 + TS-shRNA/liposome. -
Fig. 6 (A) and 6 (B) each show a time-dependent change of cell growth inhibitory rate (%) provided by pemetrexed sodium hydrate, shRNA targeting TS, or a combination of pemetrexed sodium hydrate and shRNA targeting TS in human plura malignant mesothelioma cell line METO 211 H. -
Fig. 7 shows a characteristic chart indicating tumor growth inhibitory effects confirmed for shRNA targeting TS under the presence or absence of pemetrexed sodium hydrate in mice bearing a human plura malignant mesothelioma cell line METO 211 H. - The short hairpin RNA (hereafter referred to as "shRNA") capable of inhibiting expression of thymidylate synthase (hereafter referred to as "TS") of the present invention exhibits TS-specific RNAi action when it targets an mRNA portion of thymidylate synthase. Accordingly, the short hairpin RNA can remarkably inhibit TS expression. Here, when the RNAi molecule of the present invention "targets an mRNA portion," this means that the antisense strand of shRNA described in detail below can hybridize to a target mRNA portion under stringent conditions.
- Stringent conditions can be determined based on the melting temperature (Tm) for nucleic acid at which a hybrid is formed in accordance with a conventional method. For instance, washing conditions that allows maintenance of hybridization comprise, for example, generally "1 x SSC, 0.1% SDS, 37°C," more strictly "0.5 x SSC, 0.1% SDS, 42°C," and further strictly "0.1 x SSC, 0.1% SDS, 65°C."
- The shRNA of the present invention comprises a sense strand having a nucleotide sequence of ORF encoding TS or a nucleotide sequence partially identical thereto and an antisense strand that hybridizes under stringent conditions to the sense strand. Here, the phrase "a nucleotide sequence of ORF or a nucleotide sequence partially identical thereto" means a nucleotide sequence obtained by substituting thymine with uracil in the nucleotide sequence of ORF or a nucleotide sequence partially identical thereto.
- The sense strand consists of 15 to 25 nucleotides and preferably 19 nucleotides. The nucleotide sequence of the sense strand is desirably identical to the nucleotide sequence of ORF encoding TS. However, it may be a substantially identical (i.e., homologous) sequence. Specifically, the nucleotide sequence of a sense strand may comprise the ORF nucleotide sequence including a substitution, a deletion, an insertion, and/or an addition of 1 or a plurarity of (i.e., 1 to 3) nucleotides, preferably 1 to 2 nucleotides, and more preferably 1 nucleotide.
- The antisense strand has a nucleotide sequence that can hybridize to the sense strand under stringent conditions. The antisense strand may comprise a mismatch, including a substitution, a deletion, an insertion, and/or an addition of 1 to 3 nucleotides, preferably 1 or 2 nucleotides, and more preferably 1 nucleotide as long as it can hybridize under stringent conditions. Preferably, the antisense strand consists of a nucleotide sequence perfectly complementary to the sense strand.
- The nucleotide sequences of a sense strand and an antisense strand can be selected based on a known nucleotide sequence encoding TS (GenBank: CR601528.1). There are a variety of known methods for selecting such nucleotide sequences. For example, an siRNA Design Support System (Takara Bio Inc.) can be used.
- Examples of a sense strand used in the present invention include, but are not limited to, a sense strand consisting of any of the following nucleotide sequences: 5'-GUAACACCAUCGAUCAUGA-3' (SEQ ID NO: 1); 5'-GAAUACAGAGAUAUGGAAU-3' (SEQ ID NO: 3); 5'-CGAUCAUGAUGUAGAGUGU-3' (SEQ ID NO: 5); and 5'-GGGUGUUUUGGAGGAGUUGTT-3' (SEQ ID NO: 11).
- Preferably, shRNA of the present invention comprises: a sense strand (5'-GUAACACCAUCGAUCAUGA-3'; SEQ ID NO: 1) and an antisense strand (5'-UCAUGAUCGAUGGUGUUAC-3'; SEQ ID NO: 2); a sense strand (5'-GAAUACAGAGAUAUGGAAU-3'; SEQ ID NO: 3) and an antisense strand (5'-AUUCCAUAUCUCUGUAUUC; SEQ ID NO: 4); a sense strand (5'-CGAUCAUGAUGUAGAGUGU-3'; SEQ ID NO: 5) and an antisense strand (5'-ACACUCUACAUCAUGAUCG-3'; SEQ ID NO: 6); or a sense strand (5'-GGGUGUUUUGGAGGAGUUGTT-3'; SEQ ID NO: 11) and an antisense strand (5'-AACAACUCCUCCAAAACACCC-3'; SEQ ID NO: 12).
- Further preferably, shRNA of the present invention comprises a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 1 and an antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 2.
- A sense strand and an antisense strand are linked via a linker portion. The linker portion forms a loop such that the resulting strand is folded. Accordingly, the antisense strand and the sense strand hybridize to each other, resulting in formation of a double strand. Such a linker portion contained in a shRNA molecule is not particularly limited and thus it may be a polynucleotide linker or a non-polynucleotide linker as long as it links a sense strand and an antisense strand so as to form a stem loop structure. Preferably, a polynucleotide linker is the same consisiting of 2 to 22 nucleotides known in the art. Specific examples thereof include UAGUGCUCCUGGUUG (SEQ ID NO: 7), UUCAAGAGA, CCACC, CUCGAG, CCACACC, UUCAAGAGA, AUG, CCC, and UUCG. Of these, UAGUGCUCCUGGUUG (SEQ ID NO: 7) is preferable.
- shRNA of the present invention has an overhang comprising at least 2 nucleotides at the 3' end.
- According to the present invention, the term "overhang" refers to a nucleotide added at the 3' end of an antisense strand that does not have a nucleotide capable of complementarily binding at a position corresponding to a sense strand. If an antisense strand does not have an overhang at the 3' end, the degree of TS expression inhibition caused by shRNA decreases by approximately 40% to 60% upon transfection with the use of a PEG-modified cationic liposome described in detail below, compared with a case in which an antisense strand has an overhang at the 3' end. Types or numbers of nucleotides of the overhang are not limited. For example, such overhand consists of a sequence comprising 1 to 5 nucleotides, preferably 1 to 3 nucleotides, and more preferably 1 or 2 nucleotides. Examples of a sequence include TTT, UU, and TT. Preferably, UU is used.
- According to the present invention, a preferable example of shRNA is a single strand RNA consisting of the nucleotide sequence shown in SEQ ID NO: 8.
- In addition, a sense strand or an antisense strand may be phosphorylated at the 5' end according to need. Triphosphoric acid (ppp) may be bound to the 5' end.
- In the case of the PEG-modified cationic liposome of the present invention, one or a plurality of polyethyleneglycol (PEG) molecules are covalently bound to the cationic liposome surface, allowing the cationic liposome to have improved ability to circulate in vivo.
- The cationic liposome can be produced by a known method, such as a thin film shaking method (the Bangham method) (A. D. Bangham et al., J. Mol. Biol., 13, 238-252 (1965); A. D. Bangham and R. W. Horne, J. Mol. Biol., 8, 660-668 (1964)). Specifically, at least one type of phospholipid is dissolved in an organic solvent such as chloroform in a container such as a flask. The organic solvent is evaporated to form a lipid membrane on the bottom of the container. An aqueous solution such as buffer is introduced thereinto, followed by agitation. Thus, a suspension containing liposomes can be obtained.
- The cationic liposome of the present invention has uni- or multi-lamellar membranes consisting of at least one phospholipid selected from the group consisting of dioleoylphosphatidylethanolamine (hereafter referred to as "DOPE"), palmitoyloleoylglycerophosphocholine (hereafter referred to as "POPC"), cholesterol (hereafter referred to as "CHOL") O,O'-ditetradecanoyl-N-(α-trimethylammonioacetyl)diethanolaminechloride (hereafter referred to as "DC-6-14"), hydrogenated purified yolk phosphatidylcholine, hydrogenated purified soybean phosphatidylcholine, dipalmitoyl phosphatidylcholine, distearoyl phosphatidylcholine, and 1-palmitoyl-2-oleoyl phosphatidylcholine.
- Preferably, the cationic liposome of the present invention consisits of DOPE, POPC, CHOL, and DC-6-14. The content ratio (molar ratio) of DOPE, POPC, CHOL, and DC-6-14 in the cationic liposome is DOPE : POPC : CHOL : DC-6-14 = 2 to 4 : 4 to 1 : 3 to 1 : 1 to 4 and preferably 3 : 2 : 3 : 2.
- A PEG molecule bound to the cationic liposome surface is selected from PEG molecules having molecular weights of 500 to 5000 and preferably approximately 2000. Binding of PEG to a cationic liposome can be carried out by a known method which is not particularly limited. However, a post insertion method or the like can be used. Specifically, after formation of the cationic liposome, a PEGylated phospholipid is incubated with the cationic liposome under appropriate conditions (e.g., 30°C to 60°C for 30 minutes to 3 hours). Thus, the lipid portion of the PEGylated phospholipid can be incorporated into the outer phospholipid membrane of the cationic liposome in a manner such that PEG is exposed on the cationic liposome surface. At such time, the amount of the PEGylated phospholipid used for the incorporation accounts for 3% to 10% and preferably 5% (molar percentage) of the total lipid amount of the cationic liposome. Examples of the PEGylated phospholipid that can be used according to the present invention include, but are not limited to, mPEG2000-DSPE.
- The PEG-modified cationic liposome of the present invention has a particle size of 80 to 200 nm and preferably approximately 100 nm. The PEG-modified cationic liposome of the present invention has a zeta potential of 10 to 40 mV and preferably approximately 25 mV.
- The above shRNA is covalently or noncovalently bound to the membrane surface of the PEG-modified cationic liposome. In order to bind the shRNA to the PEG-modified cationic liposome, it is desirable to intensively agitate a liquid mixture containing the shRNA and the PEG-modified cationic liposome for approximately 1 to 15 minutes and preferably 10 minutes. Agitation allows adjustment of the particle size of a PEG-modified cationic liposome containing shRNA that can be obtained to several hundred nanometers (Barichello, J. M., et al., Int. J. Pharm. 410, 153-160 (2011)). In addition, agitation allows uniform dispersion of the shRNA on the surface of PEG-modified cationic liposome at binding. Therefore, it is possible to prevent irregular tissue distribution of the PEG-modified cationic liposome due to nonuniform binding of shRNA on the liposome.
- According to the present invention, the PEG-modified cationic liposome containing shRNA has a particle size of 120 to 600 nm and preferably 200 to 300 nm. In addition, the PEG-modified cationic liposome containing shRNA has a zeta potential of 5 to 30 mV and preferably approximately 10 to 25 mV according to the present invention. The surface charge of the PEG-modified cationic liposome containing shRNA is close to neutral. In addition, the PEG-modified cationic liposome containing shRNA is unlikely to bind to a serum protein due to PEG-induced steric hindrance. Therefore, the liposome can be prevented from being trapped in lung alveoli, allowing the liposome to have improved ability to circulate in vivo.
- The PEG-modified cationic liposome containing shRNA of the present invention may contain further shRNA or siRNA targeting a different gene expressed in tumor cells, in addition to the above shRNA. Examples of "a different gene expressed in tumor cells" include, but are not limited to, genes encoding factors involved in tumor cell proliferation, for example, the growth regulatory factor group (consisting of VEGF, EGFR, PDGF, HGF, Wint, Bcl-2, survivin, and the like) and the nucleotide synthesis-related enzyme group (consisting of ribonucleotide reductase, DNA polymerase, and the like). The above shRNA and the siRNA or sh RNA targeting a different gene expressed in tumor cells may be bound to an identical PEG-modified cationic liposome or they may be separately bound to different PEG-modified cationic liposomes.
- Here, the PEG-modified cationic liposome containing shRNA is sometimes referred to as "PEG-modified lipoplex."
- As described detail in the Examples below, it is possible for the PEG-modified cationic liposome containing shRNA to inhibit tumor cell proliferation as a result of in vivo administration. Therefore, it can be used as an antitumor agent for treating cancer.
- Cancers exhibiting high TS expression levels can be treated with the antitumor agent of the present invention. Examples of such cancers include, but are not particularly limited to, colorectal cancer, liver cancer, kidney cancer, head and neck cancer, esophageal cancer, gastric cancer, biliary tract cancer, gallbladder and bile duct cancer, pancreatic cancer, lung cancer, mammary cancer, ovarian cancer, cervical cancer, uterine body cancer, bladder cancer, prostate cancer, testicular tumor, osteogenic and soft-tissue sarcomas, leukaemia, malignant lymphoma, multiple myeloma, skin cancer, brain tumor and plura malignant mesothelioma. Preferable examples are colorectal cancer, gastric cancer, head and neck cancer, lung cancer, mammary cancer, pancreatic cancer, biliary tract cancer, liver cancer and plura malignant mesothelioma. Of these, colorectal cancer and plura malignant mesothelioma are particularly preferable.
- The antitumor agent of the present invention may contain additives that can be used for production of medicines, in addition to the PEG-modified cationic liposome containing shRNA. Examples of such additives include excipients, binders, disintegrators, lubricants, diluents, solubilizers, suspending agents, isotonizing agents, pH modifiers, buffers, stabilizers, colorants, flavoring agents, corrigents, and histidine.
- Examples of excipients include lactose, sucrose, sodium chloride, glucose, maltose, mannitol, erythritol, xylitol, maltitol, inositol, dextran, sorbitol, albumin, urea, starch, calcium carbonate, kaoline, crystalline cellulose, silica, methylcellulose, glycerine, sodium alginate, gum Arabic, and a mixture of any thereof. Examples of lubricants include purified talc, stearate, sodium borate, polyethylene glycol, and a mixture of any thereof. Examples of binders include simple syrup, glucose solution, starch solution, gelatin solution, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, carboxymethyl cellulose, shellac, methylcellulose, ethyl cellulose, water, ethanol, potassium phosphate, and a mixture of any thereof. Examples of disintegrators include dry starch, sodium alginate, agar powder, laminaran powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose, and a mixture of any thereof. Examples of diluents include water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, and a mixture of any thereof. Examples of stabilizers include sodium pyrosulfife, ethylenediaminetetraacetic acid, thioglycolic acid, thiolactic acid, and a mixture of any thereof. Examples of isotonizing agents include sodium chloride, boric acid, glucose, glycerine, and a mixture of any thereof. Examples of pH modifiers and buffers include sodium citrate, citric acid, sodium acetate, sodium phosphate, and a mixture of any thereof.
- The antitumor agent of the present invention can be administered through an oral or parenteral route (e.g., intravenous administration, intraarterial administration, topical administration via injection, intraperitoneal or intrathoracic administration, subcutaneous administration, intramuscular administration, sublingual administration, percutaneous absorption, or intrarectal administration). Preferably, the antitumor agent of the present invention can be administered via intravenous administration, intraperitoneal administration, or intrathoracic administration.
- The antitumor agent of the present invention can be prepared in an adequate dosage form in accordance with the route of administration. Specifically, the antitumor agent can be prepared in various dosage forms, such as injection preparations, suspensions, emulsifiers, ointments, creams, tablets, capsules, granule preparations, powder preparations, pills, fine grains, troches, drug preparations for intrarectal administration, oleagenous suppositories, or water-soluble suppositories.
- Effects of the antitumor agent of the present invention can be evaluated by administering the antitumor agent to cells or tissues from the above cancer or individuals who have contracted the cancer, comparing the tumor sizes with the cellular or tissue tumor sizes from the above cancer or individuals who have contracted the cancer to which the antitumor agent has not been administered (or prior to administration), and confirming whether or not tumor shrinkage or disappearance can be observed. Cancer cells used for evaluation of effects of the antitumor agent of the present invention are not limited to a particular type of cancer cells, as long as TS is expressed in the cells. Examples of cancer cells used for evaluation of effects of the antitumor agent of the present invention include: human colorectal cancer cell lines such as DLD-1, DLD-1/5FU (a 5-FU-resistant DLD-1 cell line), KM12C/5FU (a 5-FU-resistant KM12C cell line), and HT29/5FU (a 5-FU-resistant HT29 cell line); and a human gastric cancer cell line such as NUGC-3/5FU (a 5-FU-resistant NUGC-3 cell line) ; and a human mesothelioma cell line (METO 211 H).
- The antitumor agent of the present invention is capable of exerting antitumor effects that are two, three, four, five, ten, twenty, thirty, forty, fifty, one hundred, or more times as great as an antitumor agent comprising RNAi molecule targeting TS mRNA as an active ingredient, which is known in the art.
- A viral vector containing DNA encoding shRNA has been conventionally used for in vivo delivery of shRNA to target cells (
WO2010/113844 ). The DNA encoding shRNA is transferred into cells by making use of water pressure upon injection of the viral vector or viral infection, resulting in intranuclear expression of shRNA. As in the case of endogenous shRNA, the expressed shRNA comes into contact with an enzyme called "dicer" such that the stem loop construct is cleaved therefrom. Thus, siRNA consisting of a double strand RNA (consisting of strands complementary to each other) is formed such that RNAi action is exhibited. Meanwhile, as a result of oral or parenteral administration of the antitumor agent of the present invention, shRNA complexed with a PEG-modified cationic liposome in the agent is delivered to tumor cells. shRNA delivered to tumor cells is transferred to the insides of cells via endocytosis. Specifically, unlike the above conventional technique, shRNA of the present invention is not shRNA expressed in target cells. The present inventors found for the first time that exogenous shRNA introduced extracellularly in vivo can exhibit RNAi action without being degraded and thus it can inhibit expression of an endogenous gene expressed in target cells. - In addition, if siRNA is coupled to a PEG-modified cationic liposome, it would be probable that a sense strand or antisense strand alone of siRNA that does not form a double strand (consisting of strands complementary to each other) would bind to the PEG-modified cationic liposome during the manufacturing process. Such PEG-modified cationic liposome containing only a sense strand or antisense strand of siRNA can be regarded as an impurity and therefore such liposome is an undesirable pharmacological product. Meanwhile, in the case of PEG-modified cationic liposome containing shRNA, such impurity is unlikely to be formed and thus the liposome can be a desirable pharmacological product.
- The antitumor agent of the present invention can be used with an existing chemotherapeutic agent. Examples of an existing chemotherapeutic agent include an antitumor agent having TS inhibitory action.
- Such "antitumor agent having TS inhibitory action" is not particularly limited as long as it can inhibit the function of TS. Examples thereof include 5-FU antitumor agents, pemetrexed sodium hydrate, raltitrexed (Tomudex), methotrexate (MTX), and OSI-7904L (OSI).
- The relationship between the TS expression level and the sensitivity of a 5-FU antitumor agent has been reported (Patrick G. Johnston et al., Cancer Res 1995; 55: 1407-12 and Kun-Huei Yeh et al., Cancer 1998; 82: 1626-31). Among cancer patients, 5-FU antitumor agents are remarkably effective for cancer patients with relatively low TS expression levels, while on the other hand, cancer patients with relatively high TS expression levels have resistance to 5-FU antitumor agents. Administraton of the antitumor agent of the present invention enables suppression of TS production in tumor tissue, allowing an increase in the sensitivity of a 5-FU antitumor agent in such tumor tissue. In addition, the PEG-modified cationic liposome is selectively accumulated in tumors when used in combination with a 5-FU antitumor agent (Yusuke Doi et al., Cancer Sci, November, 2010, vol. 101, no. 11, 2470-2475).
- When the antitumor agent of the present invention containing the PEG-modified cationic liposome is used in combination with a 5-FU antitumor agent, the agent has the above effects and thus shRNA can be delivered to tumors with good efficienty. The antitumor agent of the present invention is capable of exerting antitumor effects that are two, three, four, five, or more times as great as a 5-FU antitumor agent or the antitumor agent of the present invention used alone.
- Examples of 5-FU antitumor agents include 5-FU and a 5-FU derivative from which 5-FU is produced as an active metabolite. An example of a 5-FU derivative is an agent containing tegafur. A 5-FU derivative is preferably a compound drug containing tegafur. Specific examples thereof include a compound drug of tegafur and uracil (e.g., UFT (registered trademark) (Taiho Phamaceutical Co., Ltd.)), a compound drug of tegafur, gimeracil, and oteracil potassium. The compound drug of tegafur, gimeracil, and oteracil potassium (e.g., TS-1 (registered trademark), Taiho Phamaceutical Co., Ltd.) described below is particularly preferable. In addition, 5-FU antitumor agent is herein referred to as "S-1," or "TS-1." However, such terms can be interchangeably used.
- In addition, an example of pemetrexed sodium hydrate is Alimta (registered trademark) (Eli Lilly Japan K.K.). Also, as in the case of the 5-FU antitumor agent, shRNA can be efficiently delivered to tumors when pemetrexed sodium hydrate and the antitumor agent of the present invention are used in combination. Furthermore, a combination use of pemetrexed sodium hydrate and the antitumor agent of the present invention results in remarkably significant antitumor effects that are two, three, four, five, or more times as great as the those of pemetrexed sodium hydrate or the antitumor agent of the present invention used alone.
- The antitumor agent of the present invention can be used in combination with a different existing chemotherapeutic agent in addition to or instead of the antitumor agent having TS inhibitory action. Examples of such chemotherapeutic agent include cyclophosphamide, nitrogen mustard N-oxide, ifosfamide, melphalan, busulphan, mitobronitol, carboquone, thiotepa, ranimustine, nimustine, temozolomide, carmustine, pemetrexed disodium, methotrexate, 6-mercaptopurine riboside, mercaptopurine, doxifluridine, carmofur, cytarabine, cytarabine ocfosfate, enocitabine, gemcitabine, fludarabine, pemetrexed, cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, irinotecan hydrochloride, and capecitabine. One or a plurality of chemotherapeutic agents selected from the examples can be used. Also, as in the case of the antitumor agent having TS inhibitory action, shRNA can be efficiently delivered to tumors when the above chemotherapeutic agent and the antitumor agent of the present invention are used in combination. Furthermore, the combination use of the chemotherapeutic agent and the antitumor agent of the present invention results in remarkably significant antitumor effects two, three, four, five, or more times as great as the chemotherapeutic agent or the antitumor agent of the present invention used alone.
- A combined product of the antitumor agent of the present invention and an existing chemotherapeutic agent can be provided as long as the antitumor agent of the present invention and the existing chemotherapeutic agent are administered in combination.
- Such "combined product" may be a compound drug containing the antitumor agent of the present invention and the existing chemotherapeutic agent as active ingredients. In addition, a single package (a formulation kit) containing the antitumor agent of the present invention and the existing chemotherapeutic agent appropriate for combined administration can be produced/packaged/distributed.
- The term "combined administration" can be referred to not only simultaneous administration of the antitumor agent of the present invention and the existing chemotherapeutic agent but also administration of the antitumor agent of the present invention and the existing chemotherapeutic agent at certain intervals.
- The administration dose and the administration frequency of the antitumor agent of the present invention can vary depending on factors such as patient age and weight, and severity of disease. However, the antitumor agent of the present invention can be administered at a single dose appropriately within the range of 0.0001 mg to 100 mg in terms of shRNA per
kg body weight 1 to 3 times every day or every 1 to 21 days. The PEG-modified cationic liposome containing shRNA contained in the antitumor agent of the present invention has greater ability to circulate in vivo than a conventionally known complex (lipoplex) comprising an RNAi molecule and a liposome. Therefore, it is possible to avoid frequent administration. Such administration allows avoidance of in vivo foreign body detection by the immune system. - The administration dose and the administration frequency of the existing chemotherapeutic agent can vary depending on factors such as types of chemical substances contained as active ingredients, patient age and weight, and severity of disease. However, the existing chemotherapeutic agent can be administered at a single dose appropriately within the range of 0.0001 mg to 1000 mg per
kg body weight 1 to 3 times every day or every 1 to 14 days. For instance, if the existing chemotherapeutic agent is a 5-FU antitumor agent, it can be administered at a daily dose of 60 to 160 mg in terms of tegafur every day or every 1 to 7 days. The existing chemotherapeutic agent can be administered at lower doses and frequencies when used in combination with the antitumor agent of the present invention compared with a case in which it is administered alone. This can suppress or delay the development of side effects that can be caused by administration of the existing chemotherapeutic agents. Examples of side effects include, but are not limited to, bone-marrow suppression, hemolytic anemia, disseminated intravascular coagulation syndrome, fulminant hepatic failure, dehydration, enteritis, interstitial pneumonia, stomatitis, gastrointestinal tract ulcer, gastrointestinal tract hemorrhage, perforation of the gastrointestinal tract, acute renal failure, muco-cutaneo-ocular syndrome, toxic epidermal necrolysis, psychoneurotic disorder, acute pancreatitis, rhabdomyolysis, and anosmia. - The present invention also relates to a method for treating cancer using the antitumor agent of the present invention. Examples of cancers treatable by the method include the cancers defined above. In addition, according to the method, the administration routes and the dosages of the antitumor agent of the present invention and the existing chemotherapeutic agents are as described above.
- Hereafter, the present invention is described in greater detail with reference to the examples below. However, the present invention is not limited to these examples.
- siRNA and shRNA described below were synthesized by a conventionally known method.
- siRNA targeting TS used herein is syntheseized as the siRNA targeting TS that has been confirmed to have the antitumor effects (
W02010/113844 ). It comprises the sense strand and the antisense strand shown below. - Sense strand:
- 5'-GUAACACCAUCGAUCAUGA-3' (SEQ ID NO: 1)
- Antisense strand:
- 5'-UCAUGAUCGAUGGUGUUAC-3' (SEQ ID NO: 2)
- In addition, siRNA targeting TS is hereafter referred to as "siTS."
- siRNA targeting luciferase was synthesized as control siRNA. The siRNA comprises the sense strand and the antisense strand shown below.
- Sense strand:
- 5'-CUUACGCUGAGUACUUCGATT-3' (SEQ ID NO: 9)
- Antisense strand:
- 5'-UCGAAGUACUCAGCGUAAGTT-3' (SEQ ID NO: 10)
- In addition, siRNA targeting luciferase is hereafter referred to as "siCont."
- shRNA targeting TS used herein is syntheseized as the shRNA targeting TS that has been confirmed to have the antitumor effects (
W02010/113844 ) It comprises the following sequence.
TS-shRNA: - This shRNA differs from the aforementioned conventional shRNA targeting TS in that it has the two uracils at the 3' end (constituting an overhang). In addition, shRNA targeting TS is hereafter referred to as "shTS."
- Lipofectamine™ RNAi MAX (hereafter referred to as "Lf RNAi MAX"), which is a cationic liposome, was used as a transfection reagent.
- shRNA or siRNA prepared in Example 1 and Lf RNAi MAX were separately diluted with OptiMEM. The resulting solutions were mixed at a ratio of shRNA or siRNA to Lf RNAi MAX of 100 (pmol) : 5 (µL). Here, equivalent amounts of the shRNA or siRNA solution and the Lf RNAi MAX solution were used. The obtained liquid mixture was left at room temperature for 10 to 20 minutes, resulting in complex (lipoplex) formation.
- Each lipoplex was directly added to a 10-cm dish containing OptiMEM to adjust the total volume to 5 ml. Next, DLD-1 or DLD-1/FU cell suspension (10 ml) was seeded on the dish (500,000 cells/dish) so as to result in a final total volume of 15 ml, followed by transfection. Here, the final concentration of shRNA or siRNA was adjusted to 1, 5, or 10 nM. After the initiation of transfection, culture was carried out in a medium at 37°C under 5% CO2 for 72 hours. Then, the cell extract was prepared by the method described below.
- Seventy two (72) hours after the initiation of transfection, the medium was removed, followed by washing with cool PBS(-). Cells were detached from the dish using a trypsin solution and the supernatant was removed by centrifugation. Further, washing with cool PBS(-) was carried out. Cool Lysis buffer (50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, and Protease Inhibitor Cocktail (Sigma-Aldrich, MO,USA)) (100 to 150 µL) was added thereto, followed by incubation on ice (4°C) for 1 hour. Thus, the cells were lysed. Subsequently, centrifugation was performed (15,000 x g, 15 minutes, 4°C). The obtained supernatant was used as a cell extract.
- Equivalent amounts of the above cell extract and a 2 x sample buffer were mixed and heated using a microtube hot plate at 95°C for 3 minutes. Subsequently, centrifugation was performed for 30 seconds, followed by cooling to room temperature. Thus, an SDS-PAGE sample was obtained.
- The sample (6 µL corresponding to 9 µg of protein/lane) was applied to gel. Such gel was connected to a power supply (Bio-Rad laboratories), and electrophoresis was performed for approximately 80 minutes at a constant current of 40 mA for two gel sheets (20 mA for a single gel sheet).
- Filter paper cut in pieces with adequate sizes and Hybond-ECL were immersed in blotting buffer for pretreatment. After SDS-PAGE, a transfer apparatus was used for transferring protein to Hybond-ECL. Hybond-ECL subjected to transfer was immersed in blocking buffer (5% skim milk) for blocking at room temperature for 1 hour and washed 3 times (5 minutes each) with Tween buffer.
- For detection of TS and β-actin, overnight reaction was carried out at 4°C using the following primary antibodies each diluted with Tween buffer: a mouse monoclonal anti-human TS antibody (1:1000) (ANASPEC, Inc., CA, USA); and a mouse monoclonal anti-human β-actin antibody (1:500) (Bio Vision, Inc., CA, USA). Washing with Tween buffer was conducted 3 times (5 minutes each). Then, reaction was carried out at room temperature for 1 hour using a secondary antibody (an HRP-conjugated goat anti-mouse secondary antibody (1:2000) (MP Biomedicals, LLC, Japan)) solution diluted with Tween buffer. Washing with Tween buffer was conducted 3 times (5 minutes each), followed by a reaction with an ECL chemiluminescence reagent for approximately 1 minute. The band of each protein of interest was detected on X-ray film.
-
Fig. 1 shows the results. - It was revealed that shRNA and siRNA prepared in Example 1 can significantly inhibit TS expression in DLD-1 cells and DLD-1/FU cells. Example 3: Cancer cell (Human colorectal cancer cell) proliferation inhibitory effects of siRNA and shRNA
- In this Example, experimentaion was performed on a 96-well plate scale. A lipoplex obtained as in the case of Example 2 was directly added to wells containing OptiMEM to adjust the total volume to 50 µl per well. Next, a DLD-1 or DLD-1/FU cell (human colonic intestinal adenocarcinoma cell) suspension (2,000 cells/100 µl) was added to the wells to which the lipoplex had been added (final total volume: 150 µl), followed by transfection. Here, the final concentration of shRNA or siRNA per well was 5 nM.
- The medium was removed from each well 24 hours after the initiation of transfection. A fresh medium containing or not containing an existing chemotherapeutic agent, 5-FU, was added thereto (200 µl per well). Here, 5-FU was added to DLD-1 so as to result in a concentration of 0.1 µg/mL. 5-FU was added to DLD-1/FU so as to result in a concentration of 10 µg/mL. The medium was removed 0, 24, 48, 72, or 96 hours after the addition of the fresh medium. A 0.5% MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide) solution was added thereto (50 µL per well), followed by incubation at 37°C under 5% CO2 for 4 hours. Also, the 0.5% MTT solution was added to cell-free wells to obtain a background absorbance.
- After the completion of incubation, acidic isopropanol (150 µL) was added to each well. Formazan crystals were dissolved using a shaker. Absorbance was determined at a wavelength of 570 nm using a plate reader. Then, the cell proliferation rate was calculated.
- Cell proliferation rate (%) = [A570 (X hours after the addition of fresh medium)/A570 (0 hours after the addition of fresh medium)] x 100
-
Figs. 2 and3 show the results. - As shown in
Figs. 2 and3 , siTS and shTS were found to have significantly inhibited proliferation of DLD-1 cells and DLD-1/FU cells in the presence of 5-FU. - Cationic liposome was prepared using the Bangham method.
- Cationic lipids (i.e., DOPE, POPC, CHOL, and DC-6-14) were separately dissolved in chloroform to prepare stock solutions. A sample was collected from each stock solution by precise measurement with the use of a glass syringe so as to result in the following lipid composition: DOPE : POPC : CHOL : DC-6-14 = 3:2:3:2 (molar ratio). The samples were introduced into a plugged test tube and mixed therein (the total lipid amount: 150 mmol). Next, chloroform was removed therefrom under reduced pressure using a rotary evapolator (IWAKI, Tokyo). Subsequently, the test tube was placed overnight in a vacuum pump for complete removal of chloroform. Accordingly, a lipid thin film was formed in the test tube. A 9% sucrose solution (30 mL, pH 7.4) was added as an internal water phase to the lipid thin film, followed by intensive agitation at 37°C. Thus, the lipid thin film was completely hydrolized such that MLVs (multilamellar vesicles) were formed (final lipid concentration: 50 mM). The obtained solution was heated to 37°C, during which LUVs (large unilamellar vesicles) having particle sizes of approximately 100 nm were prepared using 200-, 100-, and 50-nm polycarbonate membranes (Nucleopore, CA, USA) by an extrusion method. The particle sizes and zeta potentials of the liposomes were determied using an NICOMP 370 (Particle Sizing System, CA, USA) (with a dinamic light scattering method and an electrophoresis light scattering method, respectively). The average particle size was found to be 119.9 nm and the zeta potential was found to be 25.56 mV for the prepared liposomes.
- The liposomes were PEGylated by a post insertion method. The liposome solution was prepared. Then, a 9% sucrose solution in which mPEG2000-DSPE had been completely dissolved was added to the liposome solution such that the molar percentage of mPEG2000-DSPE accounted for 5% of the total amount of lipids (DOPE, POPC, CHOL, and DC-6-14), followed by mild shaking in an incubator provided with a shaker at 37°C for 1 hour.
- A PEG-modified lipoplex was obtained by mixing the PEG-modified cationic liposome solution prepared in Example 4 and shTS prepared in Example 1 at a ratio of cationic liposome : shTS = 2000:1 (molar ratio), followed by intensive agitation for 10 minutes. The average particle size and zeta potential for the prepared PEG-modified lipoplex were found to be 286.8 nm and 15.81 mV, respectively.
- BALB/c nu/nu male mice were subcutaneously inoculated with a DLD-1 cell suspension (2 x 106 cells/100 µL). On
Day 8 from tumor cell inoculation, mice with tumor volumes of 50-100 mm3 were subjected to an in vivo experiment. - The PEG-modified lipoplex was administered via the mouse caudal vein to the DLD-1 tumor-bearing mice at a dose of 80 µg/300 µL (in terms of the shRNA amount) at 1-day intervals for 8 times in total starting on
day 8 after tumor transplantation. - When the existing chemotherapeutic agent ("TS-1;" Taiho Phamaceutical Co., Ltd.) was used in combination with the lipoplex, the agent was orally administered every day for 15 days at a dose of 6.9 mg (tegafur)/kg starting on
day 8 after tumor transplantation. - Carcinostatic activity was examined based on changes in tumor volume and body weight.
-
-
Figs. 4 and5 show the results. - The groups treated with the use of TS-1 or the PEG-modified lipoplex preparation alone exhibited tumor growth inhibitory effects to an extent approximately 34% greater than the control group. Meanwhile, the group treated with the combination of TS-1 and the PEG-modified lipoplex preparation exhibited tumor growth inhibitory effects to an extent approximately 66% greater than the control group. Serious toxicity, which can cause weight increase inhibition, and the like, was not confirmed for any treatment group. In addition, as shown in
Fig. 5 , it was confirmed that tumor growth can be significantly inhibited with the combined use of the PEG-modified lipoplex preparation and TS-1. - Example 7: Cancer cell (Human plura malignant mesothelioma cell) proliferation inhibitory effects of shRNA
- The experiment was carried out according to the method described in Example 3, except for using human plura malignant mesothelioma cell line (MSTO 211H) instead of human colorectal carcinoma cell line (DLD-1 or DLD-1/FU) and using pemetrexed sodium hydrate (Alimta (registered trademark) (Eli Lilly Japan K.K.)) instead of 5-FU as an exsisting chemotherapeutic agent. In the transfection, the final concentration of shRNA per well was either 5 or 10 nM. Pemetrexed sodium hydrate was added to a fresh medium at 10ng/mL
- Cell proliferation rate (%) was calcurated in the same manner as described in the Example 3.
Fig. 6 show the results. - As shown in
Fig. 6 , shTS significantly inhibited proliferation of MSTO 211H cells in the presence of pemetrexed sodium hydrate. - Example 8: Antitumor effects of PEG-modified lipoplex upon systemic administration to MSTO 211H cancer-bearing mouse MSTO 211H cancer-bearing mouse production
- BALB/c nu/nu male mice were subcutaneously inoculated with a MSTO 211H cell suspension (5 x 106 cells/100 µL). On day 14 from tumor cell inoculation, mice with tumor volumes of 50-100 mm3 were subjected to an in vivo experiment.
- The PEG-modified lipoplex prepared in Example 5 was administered via the mouse caudal vein to the MSTO 211H tumor bearing mice at a dose of 40 µg/200 µL (in terms of the shRNA amount) at 1-day intervals for 6 times in total starting on day 14 after tumor transplantation.
- When the existing chemotherapeutic agent, pemetrexed sodium hydrate (Alimta (registered trademark) (Eli Lilly Japan K.K.)), was used in combination with the lipoplex, the agent was intraperitoneally administered 6 times in total (
day - Carcinostatic activity was determined with tumor growth inhibition rate (TGI) (%) at day 21 from beginning of the administration. The TGI (%) was calculated in the same manner as described in the Example 6.
-
Figs. 7 shows the result. - The group treated with the pemetrexed sodium hydrate alone or the group treated with the PEG-modified lipoplex preparation containing shRNA targeting TS (TS shRNA) alone exhibited tumor growth inhibitory effects to an extent approximately 28% and 19%, respectively. The group treated with the combination of pemetrexed sodium hydrate and the PEG-modified lipoplex preparation containing non-targeted shRNA (NS shRNA) exhibited tumor growth inhibitory effects to an extent approximately 22%. This inhibitory effect by the combination of PMX and NS shRNA was similar to that of PMX alone. Meanwhile, the group treated with the combination of pemetrexed sodium hydrate and the PEG-modified lipoplex preparation containing shRNA targeting TS (TS shRNA) exhibited tumor growth inhibitory effects to an extent approximately 42%.
- As shown in
Fig. 7 , it was confirmed that tumor growth can be significantly inhibited with the combined use of the PEG-modified lipoplex preparation containing TS-shRNA and pemetrexed sodium hydrate. - Proliferation of TS-expressing tumor can be inhibited via in vivo administration of the antitumor agent containing, as an active ingredient, a liposome containing a shRNA molecule targeting a thymidylate synthase of the present invention. Further, if the antitumor agent is used in combination with a chemotherapeutic agent, cancer tissue targetability is promoted and thus the antitumor effects can be remarkably improved. It is expected that the present invention will contribute to the field of cancer therapy.
-
Claims (14)
- An antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3' end.
- The antitumor agent according to claim 1, wherein the shRNA comprises a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 1 and an antisense strand that hybridizes under stringent conditions to the sense strand.
- The antitumor agent according to claim 1 or 2, wherein the shRNA comprises a sense strand consisting of the nucleotide sequence shown in SEQ ID NO: 1 and an antisense strand consisting of the nucleotide sequence shown in SEQ ID NO: 2.
- The antitumor agent according to any one of claims 1 to 3, wherein the shRNA consists of the nucleotide sequence shown in SEQ ID NO: 8.
- The antitumor agent according to any one of claims 1 to 4, wherein the PEG-modified cationic liposome comprises a cationic liposome composed of dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylglycerophosphocholine (POPC), cholesterol (CHOL), and O,O'-ditetradecanoyl-N-(α-trimethylammonioacetyl)diethanolaminechloride (DC-6-14).
- The antitumor agent according to claim 5, which contains DOPE, POPC, CHOL, and DC-6-14 at a molar ratio of 3:2:3:2.
- The antitumor agent according to any one of claims 1 to 6, wherein the particle size of the antitumor agent is 200 to 300 nm.
- The antitumor agent according to any one of claims 1 to 7, wherein further siRNA or shRNA capable of inhibiting expression of a gene selected from the group consisting of genes involved in tumor cell proliferation is bound to the surface of the PEG-modified cationic liposome.
- The antitumor agent according to claim 8, wherein the gene involved in tumor cell proliferation is at least one gene selected from the group consisting of genes encoding VEGF, EGFR, PDGF, HGF, Wint, Bcl-2, survivin, ribonucleotide reductase, and DNA polymerase.
- The antitumor agent according to any one of claims 1 to 9, which is used in combination with a chemotherapeutic agent for treating tumors.
- A combined product, which contains the antitumor agent according to any one of claims 1 to 10 and a chemotherapeutic agent for treating tumors.
- The antitumor agent according to claim 10 or the combined product according to claim 11, wherein the chemotherapeutic agent for treating tumors is an antitumor agent having TS inhibitory action.
- The antitumor agent or the combined product according to claim 12, wherein the antitumor agent having TS inhibitory action is a 5-FU antitumor agent or a pemetrexed sodium hydrate.
- The antitumor agent or the combined product according to claim 13, wherein the 5-FU antitumor agent is a compound drug of tegafur, gimeracil, and oteracil potassium.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL12790050T PL2716304T3 (en) | 2011-05-23 | 2012-05-22 | A LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF |
HRP20171919TT HRP20171919T1 (en) | 2011-05-23 | 2017-12-11 | A LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011114946 | 2011-05-23 | ||
PCT/JP2012/063082 WO2012161196A1 (en) | 2011-05-23 | 2012-05-22 | LIPOSOME CONTAINING shRNA MOLECULE FOR THYMIDYLATE SYNTHASE, AND USE FOR SAME |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2716304A1 true EP2716304A1 (en) | 2014-04-09 |
EP2716304A4 EP2716304A4 (en) | 2014-10-29 |
EP2716304B1 EP2716304B1 (en) | 2017-10-11 |
Family
ID=47217272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12790050.4A Active EP2716304B1 (en) | 2011-05-23 | 2012-05-22 | A LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF |
Country Status (14)
Country | Link |
---|---|
US (1) | US20120301537A1 (en) |
EP (1) | EP2716304B1 (en) |
JP (1) | JP5941460B2 (en) |
CN (1) | CN103561775B (en) |
DK (1) | DK2716304T3 (en) |
ES (1) | ES2653923T3 (en) |
HK (1) | HK1190325A1 (en) |
HR (1) | HRP20171919T1 (en) |
HU (1) | HUE037803T2 (en) |
NO (1) | NO2716304T3 (en) |
PL (1) | PL2716304T3 (en) |
PT (1) | PT2716304T (en) |
TW (1) | TWI442927B (en) |
WO (1) | WO2012161196A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9745583B2 (en) | 2013-04-30 | 2017-08-29 | Delta-Fly Pharma, Inc. | Liposome for topical administration and application thereof |
US9855345B2 (en) | 2014-10-30 | 2018-01-02 | Delta-Fly Pharma, Inc. | Method for producing lipoplex for topical administration and antitumor agent using such lipoplex |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3494974B1 (en) | 2011-07-08 | 2023-10-18 | The University of North Carolina at Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
EP2777707A1 (en) | 2013-03-11 | 2014-09-17 | Wake Forest University Health Sciences | Method of Treating Brain Tumors |
EP3065713B1 (en) | 2013-11-06 | 2024-03-06 | The University of Chicago | Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers |
JP2017507946A (en) * | 2014-02-26 | 2017-03-23 | エスリス ゲーエムベーハーethris GmbH | Composition for gastrointestinal administration of RNA |
EP3439666A4 (en) | 2016-05-20 | 2019-12-11 | The University of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
BR112019014718A2 (en) * | 2017-01-18 | 2020-03-10 | Temasek Life Sciences Laboratory Limited | HYPEROSTABILIZED LIPOSOMES INCREASE THE DIRECTORY OF MYTHOTIC CELLS |
US20200163880A1 (en) * | 2017-07-13 | 2020-05-28 | Danmarks Tekniske Universitet | Cationic liposomes |
WO2019028250A1 (en) | 2017-08-02 | 2019-02-07 | The University Of Chicago | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, rodiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
JP6297737B1 (en) | 2017-09-25 | 2018-03-20 | ジェイ−ネットワーク,インコーポレイテッド | Method for preparing positively charged charged niosomes and charged niosomes |
CN114557964B (en) * | 2022-03-17 | 2024-03-12 | 西安艾领克生物科技有限公司 | RNA-loadable cationic shuttle-type flexible liposome and preparation method and application thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8202846B2 (en) * | 2000-03-16 | 2012-06-19 | Cold Spring Harbor Laboratory | Methods and compositions for RNA interference |
JP4543188B2 (en) * | 2004-03-10 | 2010-09-15 | 学校法人日本医科大学 | RNA sequences that act as RNAi for human thymidylate synthase |
KR20080041145A (en) * | 2005-04-12 | 2008-05-09 | 인트라디그엠 코오포레이션 | Composition and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
JP2009534342A (en) * | 2006-04-20 | 2009-09-24 | サイレンス・セラピューティクス・アーゲー | Lipoplex formulation for specific delivery to vascular endothelium |
US20090318453A1 (en) * | 2006-09-22 | 2009-12-24 | Taiho Pharmaceutical Co., Ltd | Postoperative adjuvant chemotherapy for gastric cancer |
PL2279254T3 (en) * | 2008-04-15 | 2017-11-30 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
WO2009149318A2 (en) * | 2008-06-05 | 2009-12-10 | Research Foundation Of State University Of New York | Mirnas as therapeutic targets in cancer |
CN107090454A (en) * | 2009-03-31 | 2017-08-25 | 德尔塔菲制药股份有限公司 | Target RNAi molecule and its application of thymidylate synthase |
JP5446781B2 (en) | 2009-11-26 | 2014-03-19 | トヨタ自動車株式会社 | Drive unit cooling device for left and right independent drive vehicle |
-
2011
- 2011-10-14 US US13/273,960 patent/US20120301537A1/en not_active Abandoned
-
2012
- 2012-05-22 PL PL12790050T patent/PL2716304T3/en unknown
- 2012-05-22 HU HUE12790050A patent/HUE037803T2/en unknown
- 2012-05-22 CN CN201280025004.4A patent/CN103561775B/en active Active
- 2012-05-22 JP JP2013516384A patent/JP5941460B2/en active Active
- 2012-05-22 EP EP12790050.4A patent/EP2716304B1/en active Active
- 2012-05-22 PT PT127900504T patent/PT2716304T/en unknown
- 2012-05-22 ES ES12790050.4T patent/ES2653923T3/en active Active
- 2012-05-22 NO NO12790050A patent/NO2716304T3/no unknown
- 2012-05-22 WO PCT/JP2012/063082 patent/WO2012161196A1/en active Application Filing
- 2012-05-22 DK DK12790050.4T patent/DK2716304T3/en active
- 2012-05-23 TW TW101118465A patent/TWI442927B/en active
-
2014
- 2014-04-14 HK HK14103539.6A patent/HK1190325A1/en unknown
-
2017
- 2017-12-11 HR HRP20171919TT patent/HRP20171919T1/en unknown
Non-Patent Citations (3)
Title |
---|
None * |
See also references of WO2012161196A1 * |
TAGAMI T ET AL: "Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 137, no. 3, 4 August 2009 (2009-08-04), pages 234 - 240, XP026223536, ISSN: 0168-3659, [retrieved on 20090408], DOI: 10.1016/J.JCONREL.2009.04.006 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9745583B2 (en) | 2013-04-30 | 2017-08-29 | Delta-Fly Pharma, Inc. | Liposome for topical administration and application thereof |
US9855345B2 (en) | 2014-10-30 | 2018-01-02 | Delta-Fly Pharma, Inc. | Method for producing lipoplex for topical administration and antitumor agent using such lipoplex |
Also Published As
Publication number | Publication date |
---|---|
HK1190325A1 (en) | 2014-07-04 |
EP2716304A4 (en) | 2014-10-29 |
ES2653923T3 (en) | 2018-02-09 |
TW201300113A (en) | 2013-01-01 |
TWI442927B (en) | 2014-07-01 |
NO2716304T3 (en) | 2018-03-10 |
PL2716304T3 (en) | 2018-03-30 |
DK2716304T3 (en) | 2017-11-27 |
HUE037803T2 (en) | 2018-09-28 |
CN103561775B (en) | 2016-08-17 |
JP5941460B2 (en) | 2016-06-29 |
WO2012161196A1 (en) | 2012-11-29 |
CN103561775A (en) | 2014-02-05 |
PT2716304T (en) | 2018-01-03 |
EP2716304B1 (en) | 2017-10-11 |
HRP20171919T1 (en) | 2018-02-09 |
JPWO2012161196A1 (en) | 2014-07-31 |
US20120301537A1 (en) | 2012-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2716304B1 (en) | A LIPOSOME CONTAINING shRNA MOLECULE TARGETING A THYMIDYLATE SYNTHASE AND USE THEREOF | |
EP2246056B1 (en) | Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation | |
US20100203112A1 (en) | Composition of cationic phospholipid nanoparticles for effective delivery of nucleic acids | |
KR101579638B1 (en) | Rnai molecule for thymidylate synthase and use thereof | |
EP3213755B1 (en) | New production method of lipoplex for local administration and antitumor drug using lipoplex | |
AU2013388255B2 (en) | Liposome for topical administration and application thereof | |
EP4265276A1 (en) | Composition for preventing or treating pancreatic cancer comprising peptide nucleic acid complex | |
US8592572B2 (en) | Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131118 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140925 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/713 20060101ALI20140919BHEP Ipc: A61K 9/127 20060101ALI20140919BHEP Ipc: A61K 47/24 20060101ALI20140919BHEP Ipc: A61K 48/00 20060101AFI20140919BHEP Ipc: A61K 47/28 20060101ALI20140919BHEP Ipc: A61K 45/00 20060101ALI20140919BHEP Ipc: A61K 31/513 20060101ALI20140919BHEP Ipc: C12N 15/113 20100101ALI20140919BHEP Ipc: A61K 47/18 20060101ALI20140919BHEP Ipc: A61P 35/00 20060101ALI20140919BHEP |
|
17Q | First examination report despatched |
Effective date: 20151005 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20170503 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DELTA-FLY PHARMA, INC. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 935444 Country of ref document: AT Kind code of ref document: T Effective date: 20171115 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012038455 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20171123 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20171919 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2716304 Country of ref document: PT Date of ref document: 20180103 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20171220 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20171919 Country of ref document: HR Ref country code: ES Ref legal event code: FG2A Ref document number: 2653923 Country of ref document: ES Kind code of ref document: T3 Effective date: 20180209 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D Ref country code: NO Ref legal event code: T2 Effective date: 20171011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180111 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180211 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20170403610 Country of ref document: GR Effective date: 20180518 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012038455 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 |
|
26N | No opposition filed |
Effective date: 20180712 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E037803 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20171919 Country of ref document: HR Payment date: 20190430 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180522 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20171919 Country of ref document: HR Payment date: 20200518 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171011 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171011 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20171919 Country of ref document: HR Payment date: 20210517 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 935444 Country of ref document: AT Kind code of ref document: T Effective date: 20171011 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20171919 Country of ref document: HR Payment date: 20220518 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20171919 Country of ref document: HR Payment date: 20230518 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20230511 Year of fee payment: 12 Ref country code: NO Payment date: 20230523 Year of fee payment: 12 Ref country code: NL Payment date: 20230519 Year of fee payment: 12 Ref country code: IT Payment date: 20230526 Year of fee payment: 12 Ref country code: IE Payment date: 20230522 Year of fee payment: 12 Ref country code: FR Payment date: 20230526 Year of fee payment: 12 Ref country code: DK Payment date: 20230524 Year of fee payment: 12 Ref country code: DE Payment date: 20230519 Year of fee payment: 12 Ref country code: CH Payment date: 20230605 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230518 Year of fee payment: 12 Ref country code: SE Payment date: 20230519 Year of fee payment: 12 Ref country code: PL Payment date: 20230512 Year of fee payment: 12 Ref country code: LV Payment date: 20230512 Year of fee payment: 12 Ref country code: HU Payment date: 20230523 Year of fee payment: 12 Ref country code: HR Payment date: 20230518 Year of fee payment: 12 Ref country code: GR Payment date: 20230522 Year of fee payment: 12 Ref country code: FI Payment date: 20230523 Year of fee payment: 12 Ref country code: AT Payment date: 20230522 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20230519 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230524 Year of fee payment: 12 Ref country code: ES Payment date: 20230725 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20171919 Country of ref document: HR Payment date: 20240510 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20240522 Year of fee payment: 13 |